Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404,Japanese Journal of Clinical Oncology

当前位置： X-MOL 学术 › Jpn. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
Japanese Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2021-06-12 , DOI: 10.1093/jjco/hyab084
Takashi Ninomiya _{1,

2} , Naoyuki Nogami ₃ , Toshiyuki Kozuki ₂ , Daijiro Harada ₂ , Toshio Kubo _{1,

4} , Kadoaki Ohashi ₁ , Eiki Ichihara ₅ , Shoichi Kuyama ₆ , Kenichiro Kudo ₆ , Akihiro Bessho ₇ , Makoto Sakugawa ₇ , Nobukazu Fujimoto ₈ , Keisuke Aoe ₉ , Daisuke Minami ₁₀ , Keisuke Sugimoto ₁₁ , Nobuaki Ochi ₁₂ , Nagio Takigawa ₁₂ , Katsuyuki Hotta ₁₃ , Yoshinobu Maeda ₅ , Katsuyuki Kiura ₁

Affiliation

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan.
Department of Community Medicine, Pulmonology and Cardiology, Ehime University Graduate School of Medicine, Toon, Japan.
Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Okayama, Japan.
Department of Respiratory Medicine, Iwakuni Clinical Center, Iwakuni, Japan.
Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
Department of Medical Oncology, National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Japan.
Department of Respiratory Medicine, National Hospital Organization, Okayama Medical Center, Okayama, Japan.
Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan.
Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.

In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients.

中文翻译：

接受阿法替尼和贝伐珠单抗治疗的 EGFR 突变阳性晚期非小细胞肺癌初治患者的生存率：冈山肺癌研究组试验 1404 的更新

在 I 期研究中，阿法替尼（每天 30 毫克/人）加贝伐单抗（每 3 周 15 毫克/千克）耐受性良好，并在表皮生长因子受体 ( EGFR ) 突变的晚期非小细胞肺癌患者中显示出良好的结果。肺癌。在此，我们报告了这些患者的 2 年无进展生存期、总生存期和安全性。

更新日期：2021-08-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11